Recurrent high grade serous ovarian cancer. MedDRA version: 13.1 Level: PT Classification code 10066697 Term: Ovarian cancer recurrent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Conditions
Interventions
Product Name: ABT-888
Product Code: ABT-888
Pharmaceutical Form: Capsule
INN or Proposed INN: Veliparib
CAS Number: 912444-00-9
Current Sponsor code: ABT-888
Other descriptive name: 1H-Benzimidazole-7
Sponsors
Abbott GmbH & Co. KG
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Subject must be at least 18 years of age. 2. Subject must have histologically (or cytologically) confirmed recurrent high grade serous ovarian, fallopian tube, or primary peritoneal cancer. 3. Subjects must have had at least 1 platinum containing chemotherapy regimen for ovarian cancer and no more than a total of 3 DNA damaging or cytotoxic regimens in the past 5 years. Less than a full dose of a DNA damaging agent, possibly due to reasons such as toxicity or documented allergic reaction will not be counted toward the limit of 3. Previous treatments with biologic agents (including catumaxomab, tigatuzuzumab, abagovomab and bevacizumab), vaccines, immunostimulants, hormonal agents and signal transduction inhibitors (e.g., pazoparib, sorafenib, sunitinib, temsirolimus) are allowed and are not counted towards the limit of 3. 4. Subjects who are resistant to platinum-based therapy; or sensitive to, but are unable to tolerate platinum-based therapy (i.e., deemed toxic or have a documented platinum allergy). Subjects must have at least a = 3 month treatment free interval from the last dose of platinum based therapy. They may have received other therapy since their last platinum therapy prior to enrolling in this study. 5. Subject must be eligible to receive PLD treatment (e.g., no allergic reaction, normal cardiac function). 6. Subject has either: ? Measurable disease, defined as at least 1 unidimensionally measurable lesion on a CT scan as defined by RECIST version 1.130 OR ? Non-measurable disease with an elevation of serum CA-125 level by GCIG criteria (baseline sample is at least twice the upper limit of normal and within 2 weeks prior to starting treatment).31 7. Eastern Cooperative Oncology Group (ECOG) performance score of 0 to 2. 8. Subject must have adequate hematologic, renal and hepatic function per institutional normal range as follows: ? Bone Marrow: Absolute neutrophil count (ANC = 1,500/mm3 (1.5 × 109/L); Platelets = 100,000/mm3 (100 × 109/L); Hemoglobin = 9.5 g/dL (1.4 mmol/L); ? Renal function: Serum creatinine = 1.5 × upper limit of normal (ULN) range OR creatinine clearance = 50 mL/min/1.73 m2 for subjects with creatinine levels above institutional normal; ? Hepatic function: AST and/or ALT = 2.5 × the ULN range. For subjects with liver metastases, AST and/or ALT < 5 × the ULN range; Bilirubin = 1.5 × the ULN range. ? Partial Thromboplastin Time (PTT) must be = 1.5 × the ULN range and INR < 1.5. Subjects on anticoagulant therapy (such as Coumadin) are allowed on study and will have an appropriate PTT and INR as determined by the Investigator. 9. Women of childbearing potential must agree to use adequate contraception (one of the following listed below) prior to study entry, for the duration of study participation and for 90 days following completion of therapy. Women of childbearing potential must have a negative serum pregnancy test within 21 days prior to initiation of treatment and a negative urine pregnancy test on Cycle 1 Day 1 and/or post menopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential. ? Total abstinence from sexual intercourse (minimum one complete menstrual cycle); ? Vasectomized partner; ? Hormonal contraceptives (oral, parenteral or transdermal) for at least 3 months prior to study drug administration; ? Double-barrier method (condoms, contraceptive sponge, diaphragm or vaginal ring with spermicidal jelli
Exclusion criteria
Exclusion criteria: 1. Subject has previously been treated with a PARP inhibitor except as a single dose from the CTEP Phase 0 (A06-161) study of ABT-888. 2. Subjects who have a history of hypersensitive reaction to the conventional formulation of doxorubicin HCL, or the components of PLD. 3. Subject has received anticancer agent(s) or an investigational agent within 28 days prior to study drug administration. Subjects who have not recovered to within one grade level (not to exceed grade 2) of their baseline following a significant adverse event or toxicity attributed to previous anticancer treatment are excluded. 4. Subject has undergone major surgery within the previous 28 days prior to study drug administration. 5. Subject with prior radiotherapy to any portion of the abdominal cavity and pelvis, unless for the treatment of ovarian, primary peritoneal or fallopian tube cancer. Subject must have completed radiation at least 28 days prior to study drug administration and have measurable disease outside the radiation field or documented progression of lesions within a previously radiated field. 6. Subject with a known history of brain metastases. 7. Clinically significant and uncontrolled major medical condition(s) including but not limited to: ? Active uncontrolled infection; ? Symptomatic congestive heart failure; ? Unstable angina pectoris or cardiac arrhythmia; ? Psychiatric illness/social situation that would limit compliance with study requirements. ? Any medical condition, which in the opinion of the Study Investigator, places the subject at an unacceptably high risk for toxicities. 8. Subject is pregnant or lactating. 9. Subject has been treated or hospitalized for bowel obstruction within 28 days prior to study drug administration. 10. Subject who requires parenteral nutrition or tube feeding and has evidence of partial bowel obstruction or perforation. 11. The subject has had another active malignancy within the past 5 years except for any cancer in situ considered cured or non-melanoma carcinoma of the skin. Questions regarding the inclusion of individual subject are to be directed to the Abbott Medical Monitor.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To evaluate the objective response rate (ORR) of ABT-888 in combination with Temozolomide (TMZ) compared to Pegylated Liposomal Doxorubicin (PLD) alone in subjects with recurrent high grade serous ovarian cancer.;Secondary Objective: To evaluate progression free survival (PFS), time to progression (TTP), overall survival (OS), 12-month survival rate, 6-month progression free survival rate, duration of response, safety, and tolerability.;Primary end point(s): The efficacy endpoints include objective response rate (ORR), progression-free survival (PFS), time to progression (TTP), Overall Survival (OS), 12-month survival rate, 6-month PFS rate, duration of response and ECOG performance status. Analyses of these endpoints are described in Section 8.1.2.;Timepoint(s) of evaluation of this end point: Screening to survival follow-up (approx. every 12 weeks or as needed for up to 3 yrs) | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): Progression Free Survival, Time to Progression, Overall Survival, 12-month Survival Rate, 6-month Progression Survival Rate, Duration of Response, Safety and Tolerability;Timepoint(s) of evaluation of this end point: Screening to survival follow-up (approx. every 12 weeks or as needed for up to 3 yrs) | — |
Countries
Argentina, Australia, Canada, Hungary, Israel, New Zealand, United Kingdom, United States
Contacts
Public ContactClinical Trial Application
Abbott Laboratories
Outcome results
None listed